Marina completes dosing of second cohort in Phase Ib START-FAP trial
The three patients of cohort 2 received a dose of 1×10(9) colony forming units (cfu)/day for up to 28 days of continuous oral dosing. Dosing of third cohort
The European Commission (EC) has granted marketing authorisation for Revolution Medicines’ Rasonque (daraxonrasib) to treat adult patients with metastatic pancreatic adenocarcinoma who have undergone at least one systemic therapy earlier.